Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

Clinical Care/Education/Nutrition

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

¹Department of Medicine and the Northwest Lipid Research Clinic, University of Washington School of Medicine, Seattle, Washington
²Department of Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
³Department of Internal Medicine, Refaja-Hospital, Stadskanaal, the Netherlands
⁴Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, U.K.

Address correspondence and reprint requests to Chief Robert H. Knopp, Harborview Medical Center, 325 Ninth Ave., #359720, Seattle, WA 98104-2499. E-mail: rhknopp{at}u.washington.edu

Diabetes Care 2006 Jul; 29(7): 1478-1485. https://doi.org/10.2337/dc05-2415

vol. 29 no. 7 1478-1485

DOI

PubMed

Published By

Print ISSN

Online ISSN

History

DIABETES CARE

¹Department of Medicine and the Northwest Lipid Research Clinic, University of Washington School of Medicine, Seattle, Washington
²Department of Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
³Department of Internal Medicine, Refaja-Hospital, Stadskanaal, the Netherlands
⁴Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, U.K.

Address correspondence and reprint requests to Chief Robert H. Knopp, Harborview Medical Center, 325 Ninth Ave., #359720, Seattle, WA 98104-2499. E-mail: rhknopp{at}u.washington.edu